Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T cells, forming ...

Prostate cancer is the most common urologic cancer, with PSA screening reducing mortality by up to 20% in men aged 55–69. Bladder cancer incidence is stable, with early detection through urine ...

"My second book is on pelvic pain or prostatitis. It is focused on a holistic approach and stretches and mindfulness exercises," says Vanita Gaglani, RPT. In this video, Vanita Gaglani, RPT, discusses ...

"A lot of shared decision-making has to do with, what is important to the individual man?" says Dean S. Elterman, MD, MSc, FRCSC. In this interview, Dean S. Elterman, MD, MSc, FRCSC, gives an overview ...

ctDNA in metastatic RCC shows high concordance with disease progression and indolence in negative cases, indicating its prognostic value. A clinical trial is underway to explore treatment ...

“I would say both there could be an increase in MRI-guided [SBRT] and there may be increase in investigation into shrinking margins with CT-guided SBRT as well,” says Amar U. Kishan, MD. In this video ...

All nine patients with stage III/IV ccRCC showed anti-tumor responses and remained disease-free three years post-vaccination. The vaccine induced durable T cell activation and immune responses against ...

Panelists discuss how for patients with BCG-unresponsive bladder cancer, treatment selection depends on key factors including tumor characteristics (carcinoma in situ vs papillary), patient fitness, ...

"There are actually no data to support that 1 neuromodulation is better than another based on disease severity, and this is based on the systematic review done for the OAB guideline," says Anne ...

The Revi System showed sustained efficacy at 24 months, with 79% of patients responding to therapy and significant reductions in UUI episodes. Patient satisfaction was high, with 97% satisfied and 80% ...

Panelists explore challenges in identification of patients with intermediate-risk disease and emphasize importance of risk stratification to improve outcomes with regard to NMIBC.